Category: St. Jude Medical
A look at some of the top medical device companies suggests that the long-lamented medical device tax hasn't had much of an impact on their research & development budgets.
MASSDEVICE ON CALL — Despite repeated warnings and laments, the medical device tax implemented with healthcare reform hasn't appeared to make much of a dent in the industry's research & development activities, according to a small report.
St. Jude Medical says that its next-gen EnligHTN renal denervation system appears safe and effective in treating hypertension, but docs at this year's EuroPCR conference are calling for more robust clinical trials.
Here's a look at some of the top Wall Street stories for medical device companies this week: Abbott may look to expand medical device business footprint; Device makers take big writedowns on renal denervation; Cardinal Health closes $320M AccessClosure buy; K2M prices IPO under range at $132M; Allergan board spurns Valeant's $47B offer.
Access Closure Inc.
, Boston Scientific
, Cardinal Health
, Pershing Square Capital Management
, St. Jude Medical
, Valeant Pharmaceuticals
, Abbott Laboratories
, Allergan Inc.
St. Jude Medical launches a U.S. study of its Portico transcatheter aortic valve in patients who are not candidates for open heart surgery.
Minnesota medtech maker St. Jude Medical (NYSE:STJ) launched a U.S. study of its Portico catheter-based aortic valve, enrolling the 1st patients in pursuit of FDA approval for the implant.
Boston Scientific, Medtronic and Covidien take millions in write-downs on their renal denervation assets after the failure of Medtronic's Symplicity-3 trial.
Two perforation-related deaths and 4 additional adverse events temporarily derail enrollment in St. Jude Medical's European Nanostim registry as the company evaluates the patient injuries.
Updated May 12, 2014, at 5:30 p.m. with confirmation from St. Jude Medical.
Medtech's biggest players release a slew of new reports at this year's Heart Rhythm Society conference, with Medtronic data on preventive shocks for ICD patients, lowered mortality for patients remotely monitored with Boston Scientific's LATITUDE system, and more.